Deltex Medical Group (DEMG) Share Price, News & Analysis

Company Overview

Deltex Medical’s technology Deltex Medical’s TrueVue System uses proprietary haemodynamic monitoring technology to assist clinicians to improve outcomes for patients as well as increase throughput and capacity for hospitals. Deltex Medical has invested over the long term to build a unique body of peer-reviewed, published evidence from a substantial number of trials carried out around the world. These studies demonstrate statistically significant improvements in clinical outcomes providing benefits both to patients and to the hospital systems by increasing patient throughput and expanding hospital capacity. The Group’s flagship, world-leading, ultrasound-based oesophageal Doppler monitoring (“ODM”) is supported by 24 randomised control trials conducted on anaesthetised patients. As a result, the primary application for ODM is focussed on guiding therapy for patients undergoing elective surgery. Deltex Medical’s engineers and scientists carried out successful research in conjunction with the UK’s National Physical Laboratory (“NPL”), which has enabled the Group’s ‘gold standard’ ODM technology to be extended and developed so that it can be used completely noninvasively. This will significantly expand the application of Deltex Medical’s technology to non-sedated patients. This new technological enhancement, which will be released on the new next generation monitor, will substantially increase the addressable market for the Group’s haemodynamic monitoring technologies and is complementary to the long-established ODM evidence base. Deltex Medical’s new non-invasive technology has potential applications for use in a number of healthcare settings, including: ▪ Accident & Emergency for the rapid triage of patients, including the detection and diagnosis of sepsis, an important capability for patients presenting with COVID-19 symptoms; ▪ in general wards to help facilitate a real-time, data-driven treatment regime for patients whose condition might deteriorate rapidly; and ▪ in critical care units to allow regular monitoring of patients post-surgery who are no longer sedated or intubated. One of the key opportunities for the Group is positioning this new, non-invasive technology for use throughout the hospital. Deltex Medical’s haemodynamic monitoring technologies provide clinicians with beat-to-beat real-time information on a patient’s circulating blood volume and heart function. This information is critical to enable clinicians to optimise both fluid and drug delivery to patients. Deltex Medical’s business model is to drive the recurring revenues associated with the sale of single-use disposable ODM probes which are used in the TrueVue System and to complement these revenues with a new incremental revenue stream to be derived from the Group’s new non-invasive technology. Both the existing single-use ODM probe and the new, non-invasive device will connect to the same, next generation monitor which is due for launch in 2023. Monitors are sold or, due to hospitals’ often protracted procurement times for capital items, loaned in order to encourage faster adoption of the Group’s technology. Deltex Medical’s customers The principal users of Deltex Medical’s products are currently anaesthetists working in a hospital’s operating theatre and intensivists working in ICUs. This customer profile will change as the Group’s new non-invasive technology is adopted by the market. In the UK the Group sells directly to the NHS. In the USA the Group sells directly to more than 30 major hospitals that appreciate the value of Deltex Medical’s evidence-based approach to haemodynamic management. The Group also sells through distributors in more than 40 countries in the European Union, Asia and the Americas. Deltex Medical’s objective To see the adoption of Deltex Medical’s next generation TrueVue System, comprising both minimally invasive and non-invasive technologies, as the standard of care in haemodynamic monitoring for all patients from new-born to adult, awake or anaesthetised, across all hospital settings globally. For further information please go to www.deltexmedical.com

Key Stats

• Today's Range: 0.04 to 0.05
• 50-Day Range: 0.04 to 0.09
• 52-Week Range: 0.02 to 0.20
• Volume: 11.11 million shs
• Average Volume: 20.17 million shs
• Market Capitalization: £684,000.00
• P/E Ratio: N/A
• Dividend Yield: 2.19%
• Price Target: N/A
• Consensus Rating: N/A

DEMG Stock Analysis - Frequently Asked Questions

How have DEMG shares performed this year?

Deltex Medical Group's stock was trading at GBX 0.08 at the start of the year. Since then, DEMG shares have decreased by 56.6% and is now trading at GBX 0.04.
View the best growth stocks for 2025 here.

How were Deltex Medical Group's earnings last quarter?

Deltex Medical Group plc (LON:DEMG) announced its quarterly earnings results on Monday, September, 21st. The company reported ($0.11) earnings per share for the quarter. Deltex Medical Group had a negative trailing twelve-month return on equity of 57.02% and a negative net margin of 72.49%.

How do I buy shares of Deltex Medical Group?

Shares of DEMG stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Deltex Medical Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Deltex Medical Group investors own include Indivior (INDV), Nanoco Group (NANO), Tullow Oil (TLW), Ocado Group (OCDO), Bigblu Broadband (BBB), B&M European Value Retail (BME) and BP (BP).

Company Calendar

• Last Earnings: 9/21/2020
• Today: 1/22/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: N/A
• Current Symbol: LON:DEMG
• CUSIP: N/A
• CIK: N/A
• Web: www.deltexmedical.com
• Phone: +44-1243-774837
• Fax: N/A
• Employees: 37
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 7.42
• P/E Growth: N/A
• Net Income: £-1,290,000.00
• Net Margins: -72.49%
• Pretax Margin: N/A
• Return on Equity: -57.02%
• Return on Assets: -7.77%

Debt

• Debt-to-Equity Ratio: 73.77
• Current Ratio: 0.89
• Quick Ratio: 0.59

Sales & Book Value

• Annual Sales: £1.78 million
• Price / Sales: 0.38
• Cash Flow: GBX 0 per share
• Price / Cash Flow: 9.00
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,900,000,000
• Free Float: N/A
• Market Cap: £684,000.00
• Optionable: Not Optionable
• Beta: 0.78